Encore Medical have just received pre-market approval from the US Food and Drug Administration (FDA) for their ceramic-on-ceramic acetabular hip replacement.
Encore’s new offering is marketed under the name Keramos and is suited to younger more active patients as it has improved longer term performance, reducing the likelihood of the need for revision surgery, especially when compared to polymeric (polyethylene) and metallic implants.
The Keramos range of implants use alumina as the ceramic material. The new ceramic-on-ceramic system adds to current offerings of ceramic-on-polyethylene, metal-on-polyethylene and metal-on-metal systems.
For more information on hip replacements, click here.